Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Assess whether Risk Parity or index funds better suit your retirement plan by examining diversification, cost, and potential risk/return trade-offs.
27,926 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Craving a position in SpaceX before it goes public? An ETF that blends public and late-stage private exposure, like X...
Privacy-focused crypto Zcash is quietly advancing features that could challenge Bitcoin and Ethereum. This in-depth g...
Bitcoin trades within a broad range as traders watch a historic buy zone. ETF-driven liquidity and macro shifts could...
Oil markets roiled by Hormuz disruptions push energy ETFs past the 50% mark for the year, prompting a closer look at ...
Discover how Marek Capital's co-founder approaches credit, risk, and portfolio design. This practical, investor-focus...
A new proposal aims to end blind signing in Ethereum wallets. The change could reduce scam losses and tighten securit...
SpaceX lit up the market with a big debut, yet the price tag raised serious questions. This article breaks down why m...
As SpaceX eyes an IPO, investors wonder how Starlink's trajectory could change. This guide breaks down potential futu...
A renowned marine biologist was shot dead in the Philippines after warning that coral loss could destabilize oceans. ...
Conflicts in the Persian Gulf threaten the region’s desalination network, risking drinking water supplies for million...
As the infrastructure megatrend gathers steam, a single ETF could anchor your 2026 strategy. Learn which fund stands ...